GlassScriptPhysician profile
Esber S Samara
NPI 1336130756
$2,714.03
in general payments reported to CMS, 2019-2025
30 companies · $155 in 2025
The $155 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $838 · 2020: $248 · 2021: $646 · 2022: $227 · 2023: $241 · 2024: $358 · 2025: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $754.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $607.54 | 2019-2024 | |
| Boston Scientific Corporation | $502.02 | 2019-2021 | |
| Veloxis Pharmaceuticals, INC. | $162.02 | 2022-2025 | Envarsus |
| Vifor Pharma, INC. | $125.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $120.47 | 2019 | |
| Travere Therapeutics, INC. | $106.81 | 2019-2024 | |
| Ethicon US, LLC | $99.07 | 2021 | |
| Accord Healthcare, INC. | $96.08 | 2023-2024 | |
| Urogen Pharma, INC. | $92.76 | 2023-2025 | Jelmyto |
| Genzyme Corporation | $91.85 | 2019 | |
| Astellas Pharma US INC | $75.29 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $65.21 | 2019 | |
| Ferring Pharmaceuticals INC. | $54.63 | 2019-2024 | Adstiladrin |
| Janssen Biotech, INC. | $49.74 | 2022-2023 | Erleada |
| Bayer Healthcare Pharmaceuticals INC. | $47.30 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar Pharmaceuticals, INC. | $44.72 | 2020-2022 | |
| Procept Biorobotics Corporation | $44.33 | 2023-2024 | Aquabeam System, Aquabeam Robotic System |
| Laborie Medical Technologies Corp. | $42.65 | 2025 | |
| Sumitomo Pharma America, INC. | $36.63 | 2023 | Gemtesa |
| Cook Medical LLC | $32.97 | 2019-2020 | |
| Vertex Pharmaceuticals Incorporated | $32.09 | 2025 | |
| Clarus Therapeutics INC. | $29.62 | 2021 | |
| Coloplast Corp | $27.16 | 2021 | |
| Alexion Pharmaceuticals, INC. | $21.13 | 2023 | Ultomiris |
| Myovant Sciences INC. | $20.90 | 2021 | |
| La Jolla Pharmaceutical Company | $20.40 | 2019 | |
| Tolmar, INC. | $17.59 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $16.86 | 2019 | |
| Eurofins Viracor, LLC | $16.37 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $14.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Esber Samara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.